These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31494172)

  • 1. N1-methylnicotinamide as a possible modulator of cardiovascular risk markers in polycystic ovary syndrome.
    Nejabati HR; Samadi N; Roshangar L; Nouri M
    Life Sci; 2019 Oct; 235():116843. PubMed ID: 31494172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotinamide and its metabolite N1-Methylnicotinamide alleviate endocrine and metabolic abnormalities in adipose and ovarian tissues in rat model of Polycystic Ovary Syndrome.
    Nejabati HR; Samadi N; Shahnazi V; Mihanfar A; Fattahi A; Latifi Z; Bahrami-Asl Z; Roshangar L; Nouri M
    Chem Biol Interact; 2020 Jun; 324():109093. PubMed ID: 32298659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A visceral adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome.
    Ehsani B; Moslehi N; Mirmiran P; Ramezani Tehrani F; Tahmasebinejad Z; Azizi F
    Clin Nutr; 2016 Oct; 35(5):1181-7. PubMed ID: 26699405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
    Lie Fong S; Laven JSE; Duhamel A; Dewailly D
    Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
    Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
    Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome.
    Barber TM; Vojtechova P; Franks S
    Horm Mol Biol Clin Investig; 2013 Sep; 15(3):91-103. PubMed ID: 25436736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome.
    Gateva AT; Kamenov ZA
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):161-6. PubMed ID: 22727921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemostatic abnormalities and relationships to metabolic and hormonal status in polycystic ovarian syndrome.
    Burchall G; Linden MD; Teede H; Piva TJ
    Trends Cardiovasc Med; 2011 Jan; 21(1):6-14. PubMed ID: 22498014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
    Fraissinet A; Robin G; Pigny P; Lefebvre T; Catteau-Jonard S; Dewailly D
    Hum Reprod; 2017 Aug; 32(8):1716-1722. PubMed ID: 28854589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women].
    Orio F; Cascella T; Giallauria F; Palomba S; De Lorenzo A; Lucci R; Ambrosino E; Lombardi G; Colao A; Vigorito C
    Monaldi Arch Chest Dis; 2006 Mar; 66(1):48-53. PubMed ID: 17125045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotinamide-N-methyltransferase regulates lipid metabolism via SAM and 1-methylnicotinamide in the AML12 hepatocyte cell line.
    Yoda M; Mizuno R; Izumi Y; Takahashi M; Bamba T; Kawaoka S
    J Biochem; 2023 Jun; 174(1):89-98. PubMed ID: 37014628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
    Graff SK; Mário FM; Alves BC; Spritzer PM
    Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N1-Methylnicotinamide: An Anti-Ovarian Aging Hormetin?
    Nejabati HR; Schmeisser K; Shahnazi V; Samimifar D; Faridvand Y; Bahrami-Asl Z; Fathi-Maroufi N; Nikanfar S; Nouri M
    Ageing Res Rev; 2020 Sep; 62():101131. PubMed ID: 32711159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pluripotential effects of hypolipidemic treatment for polycystic ovary syndrome (PCOS): dyslipidemia, cardiovascular risk factors and beyond.
    Economou F; Xyrafis X; Christakou C; Diamanti-Kandarakis E
    Curr Pharm Des; 2011; 17(9):908-21. PubMed ID: 21418035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia: Results of a longitudinal study with community controls.
    Huddleston HG; Quinn MM; Kao CN; Lenhart N; Rosen MP; Cedars MI
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):775-782. PubMed ID: 29044581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome.
    Lambrinoudaki I
    Maturitas; 2011 Jan; 68(1):13-6. PubMed ID: 20943333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.
    Torchen LC
    Curr Diab Rep; 2017 Nov; 17(12):137. PubMed ID: 29128916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovary syndrome.
    Azziz R; Carmina E; Chen Z; Dunaif A; Laven JS; Legro RS; Lizneva D; Natterson-Horowtiz B; Teede HJ; Yildiz BO
    Nat Rev Dis Primers; 2016 Aug; 2():16057. PubMed ID: 27510637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
    Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
    Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.